Report cover image

Global PET Radiopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 192 Pages
SKU # APRC20552430

Description

Summary

According to APO Research, The global PET Radiopharmaceuticals market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for PET Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for PET Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for PET Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for PET Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of PET Radiopharmaceuticals include Cardinal Health Inc. (U.S.), Bayer AG (Germany), Nordion, Inc. (Canada), Mallinckrodt plc (Ireland), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), GE Healthcare (U.K.), Eczacibasi-Monrol Nuclear Products (Turkey) and Bracco Imaging S.p.A (Italy), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for PET Radiopharmaceuticals, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of PET Radiopharmaceuticals, also provides the sales of main regions and countries. Of the upcoming market potential for PET Radiopharmaceuticals, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the PET Radiopharmaceuticals sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global PET Radiopharmaceuticals market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for PET Radiopharmaceuticals sales, projected growth trends, production technology, application and end-user industry.

PET Radiopharmaceuticals Segment by Company

Cardinal Health Inc. (U.S.)
Bayer AG (Germany)
Nordion, Inc. (Canada)
Mallinckrodt plc (Ireland)
Lantheus Medical Imaging, Inc. (U.S.)
IBA Molecular Imaging (Belgium)
GE Healthcare (U.K.)
Eczacibasi-Monrol Nuclear Products (Turkey)
Bracco Imaging S.p.A (Italy)
Advanced Accelerator Applications S.A. (France)
PET Radiopharmaceuticals Segment by Type

F-18
Ru-82
Others
PET Radiopharmaceuticals Segment by Application

Neurology
Cardiology
Oncology
Others
PET Radiopharmaceuticals Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PET Radiopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PET Radiopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PET Radiopharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PET Radiopharmaceuticals market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of PET Radiopharmaceuticals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of PET Radiopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of PET Radiopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

192 Pages
1 Market Overview
1.1 Product Definition
1.2 Global PET Radiopharmaceuticals Market Size, 2020 VS 2024 VS 2031
1.3 Global PET Radiopharmaceuticals Market Size Estimates and Forecasts (2020-2031)
1.4 Global PET Radiopharmaceuticals Sales Estimates and Forecasts (2020-2031)
1.5 Global PET Radiopharmaceuticals Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global PET Radiopharmaceuticals Market Dynamics
2.1 PET Radiopharmaceuticals Industry Trends
2.2 PET Radiopharmaceuticals Industry Drivers
2.3 PET Radiopharmaceuticals Industry Opportunities and Challenges
2.4 PET Radiopharmaceuticals Industry Restraints
3 PET Radiopharmaceuticals Market by Manufacturers
3.1 Global PET Radiopharmaceuticals Revenue by Manufacturers (2020-2025)
3.2 Global PET Radiopharmaceuticals Sales by Manufacturers (2020-2025)
3.3 Global PET Radiopharmaceuticals Average Sales Price by Manufacturers (2020-2025)
3.4 Global PET Radiopharmaceuticals Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global PET Radiopharmaceuticals Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global PET Radiopharmaceuticals Manufacturers, Product Type & Application
3.7 Global PET Radiopharmaceuticals Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global PET Radiopharmaceuticals Market CR5 and HHI
3.8.2 Global Top 5 and 10 PET Radiopharmaceuticals Players Market Share by Revenue in 2024
3.8.3 2024 PET Radiopharmaceuticals Tier 1, Tier 2, and Tier 3
4 PET Radiopharmaceuticals Market by Type
4.1 PET Radiopharmaceuticals Type Introduction
4.1.1 F-18
4.1.2 Ru-82
4.1.3 Others
4.2 Global PET Radiopharmaceuticals Sales by Type
4.2.1 Global PET Radiopharmaceuticals Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global PET Radiopharmaceuticals Sales by Type (2020-2031)
4.2.3 Global PET Radiopharmaceuticals Sales Market Share by Type (2020-2031)
4.3 Global PET Radiopharmaceuticals Revenue by Type
4.3.1 Global PET Radiopharmaceuticals Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global PET Radiopharmaceuticals Revenue by Type (2020-2031)
4.3.3 Global PET Radiopharmaceuticals Revenue Market Share by Type (2020-2031)
5 PET Radiopharmaceuticals Market by Application
5.1 PET Radiopharmaceuticals Application Introduction
5.1.1 Neurology
5.1.2 Cardiology
5.1.3 Oncology
5.1.4 Others
5.2 Global PET Radiopharmaceuticals Sales by Application
5.2.1 Global PET Radiopharmaceuticals Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global PET Radiopharmaceuticals Sales by Application (2020-2031)
5.2.3 Global PET Radiopharmaceuticals Sales Market Share by Application (2020-2031)
5.3 Global PET Radiopharmaceuticals Revenue by Application
5.3.1 Global PET Radiopharmaceuticals Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global PET Radiopharmaceuticals Revenue by Application (2020-2031)
5.3.3 Global PET Radiopharmaceuticals Revenue Market Share by Application (2020-2031)
6 Global PET Radiopharmaceuticals Sales by Region
6.1 Global PET Radiopharmaceuticals Sales by Region: 2020 VS 2024 VS 2031
6.2 Global PET Radiopharmaceuticals Sales by Region (2020-2031)
6.2.1 Global PET Radiopharmaceuticals Sales by Region (2020-2025)
6.2.2 Global PET Radiopharmaceuticals Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America PET Radiopharmaceuticals Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America PET Radiopharmaceuticals Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe PET Radiopharmaceuticals Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe PET Radiopharmaceuticals Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific PET Radiopharmaceuticals Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific PET Radiopharmaceuticals Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa PET Radiopharmaceuticals Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa PET Radiopharmaceuticals Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global PET Radiopharmaceuticals Revenue by Region
7.1 Global PET Radiopharmaceuticals Revenue by Region
7.1.1 Global PET Radiopharmaceuticals Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global PET Radiopharmaceuticals Revenue by Region (2020-2025)
7.1.3 Global PET Radiopharmaceuticals Revenue by Region (2026-2031)
7.1.4 Global PET Radiopharmaceuticals Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America PET Radiopharmaceuticals Revenue (2020-2031)
7.2.2 North America PET Radiopharmaceuticals Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe PET Radiopharmaceuticals Revenue (2020-2031)
7.3.2 Europe PET Radiopharmaceuticals Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific PET Radiopharmaceuticals Revenue (2020-2031)
7.4.2 Asia-Pacific PET Radiopharmaceuticals Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa PET Radiopharmaceuticals Revenue (2020-2031)
7.5.2 South America, Middle East and Africa PET Radiopharmaceuticals Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Cardinal Health Inc. (U.S.)
8.1.1 Cardinal Health Inc. (U.S.) Comapny Information
8.1.2 Cardinal Health Inc. (U.S.) Business Overview
8.1.3 Cardinal Health Inc. (U.S.) PET Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Cardinal Health Inc. (U.S.) PET Radiopharmaceuticals Product Portfolio
8.1.5 Cardinal Health Inc. (U.S.) Recent Developments
8.2 Bayer AG (Germany)
8.2.1 Bayer AG (Germany) Comapny Information
8.2.2 Bayer AG (Germany) Business Overview
8.2.3 Bayer AG (Germany) PET Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Bayer AG (Germany) PET Radiopharmaceuticals Product Portfolio
8.2.5 Bayer AG (Germany) Recent Developments
8.3 Nordion, Inc. (Canada)
8.3.1 Nordion, Inc. (Canada) Comapny Information
8.3.2 Nordion, Inc. (Canada) Business Overview
8.3.3 Nordion, Inc. (Canada) PET Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Nordion, Inc. (Canada) PET Radiopharmaceuticals Product Portfolio
8.3.5 Nordion, Inc. (Canada) Recent Developments
8.4 Mallinckrodt plc (Ireland)
8.4.1 Mallinckrodt plc (Ireland) Comapny Information
8.4.2 Mallinckrodt plc (Ireland) Business Overview
8.4.3 Mallinckrodt plc (Ireland) PET Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Mallinckrodt plc (Ireland) PET Radiopharmaceuticals Product Portfolio
8.4.5 Mallinckrodt plc (Ireland) Recent Developments
8.5 Lantheus Medical Imaging, Inc. (U.S.)
8.5.1 Lantheus Medical Imaging, Inc. (U.S.) Comapny Information
8.5.2 Lantheus Medical Imaging, Inc. (U.S.) Business Overview
8.5.3 Lantheus Medical Imaging, Inc. (U.S.) PET Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Lantheus Medical Imaging, Inc. (U.S.) PET Radiopharmaceuticals Product Portfolio
8.5.5 Lantheus Medical Imaging, Inc. (U.S.) Recent Developments
8.6 IBA Molecular Imaging (Belgium)
8.6.1 IBA Molecular Imaging (Belgium) Comapny Information
8.6.2 IBA Molecular Imaging (Belgium) Business Overview
8.6.3 IBA Molecular Imaging (Belgium) PET Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 IBA Molecular Imaging (Belgium) PET Radiopharmaceuticals Product Portfolio
8.6.5 IBA Molecular Imaging (Belgium) Recent Developments
8.7 GE Healthcare (U.K.)
8.7.1 GE Healthcare (U.K.) Comapny Information
8.7.2 GE Healthcare (U.K.) Business Overview
8.7.3 GE Healthcare (U.K.) PET Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 GE Healthcare (U.K.) PET Radiopharmaceuticals Product Portfolio
8.7.5 GE Healthcare (U.K.) Recent Developments
8.8 Eczacibasi-Monrol Nuclear Products (Turkey)
8.8.1 Eczacibasi-Monrol Nuclear Products (Turkey) Comapny Information
8.8.2 Eczacibasi-Monrol Nuclear Products (Turkey) Business Overview
8.8.3 Eczacibasi-Monrol Nuclear Products (Turkey) PET Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Eczacibasi-Monrol Nuclear Products (Turkey) PET Radiopharmaceuticals Product Portfolio
8.8.5 Eczacibasi-Monrol Nuclear Products (Turkey) Recent Developments
8.9 Bracco Imaging S.p.A (Italy)
8.9.1 Bracco Imaging S.p.A (Italy) Comapny Information
8.9.2 Bracco Imaging S.p.A (Italy) Business Overview
8.9.3 Bracco Imaging S.p.A (Italy) PET Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Bracco Imaging S.p.A (Italy) PET Radiopharmaceuticals Product Portfolio
8.9.5 Bracco Imaging S.p.A (Italy) Recent Developments
8.10 Advanced Accelerator Applications S.A. (France)
8.10.1 Advanced Accelerator Applications S.A. (France) Comapny Information
8.10.2 Advanced Accelerator Applications S.A. (France) Business Overview
8.10.3 Advanced Accelerator Applications S.A. (France) PET Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Advanced Accelerator Applications S.A. (France) PET Radiopharmaceuticals Product Portfolio
8.10.5 Advanced Accelerator Applications S.A. (France) Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 PET Radiopharmaceuticals Value Chain Analysis
9.1.1 PET Radiopharmaceuticals Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 PET Radiopharmaceuticals Production Mode & Process
9.2 PET Radiopharmaceuticals Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 PET Radiopharmaceuticals Distributors
9.2.3 PET Radiopharmaceuticals Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.